ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR ...

CRISPR biotech Scribe Therapeutics set a $13-$15 price range for its $100 million IPO, signaling confidence as gene-editing investments regain momentum after years of sector skepticism. Scribe ...

Once again showing the sad condition of rural school infrastructure in the Garo Hills region, a recently upgraded higher secondary school in Rongmil in the district of East Garo Hills (EGH), which was ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million ...

Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. The Bay Area biotech already disclosed earlier this ...

Creator Liam Thompson hand-paints every line of the Shrek script across an entire wall.

For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to ...

This article first appeared on GuruFocus. Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial ...

As adoption of AI ambient scribe technology rapidly grows, the healthcare industry's standard method for evaluating clinical AI notes may be fundamentally flawed, failing to detect significant errors ...

Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, is seeking to raise as much as $107.2 million in a US initial public offering. The Alameda, California-based ...

Scribe Therapeutics Inc. (SCTX) has filed to raise drug development investment in an IPO, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing gene editing ...